⁠Invest In Assets 📈
RT @InvestInAssets: 50 Quality businesses: https://t.co/0CVi6xu6jJ
tweet

⁠Lumida Wealth Management
1/ Daily News Round-Up:

- China’s factories turn to robots amid labor shortages.
- Bitcoin kicks off September at $58.5K, facing historical bearish trends.
- Intel’s shares plunge, risking Dow exit.
- Global stocks pull back as traders await US economic data.
- BMW recalls 140K Mini Coopers over battery fire risk. 

#News #Bitcoin #China #Intel #BMW
tweet

⁠Quality Investing with Aria
About to go sit in an accounting class that teaches me

“Profit = revenue - costs”

This should be fun 🥴 🤩 https://t.co/rgMdJ7JyPN
tweet

⁠Hidden Value Gems
Quote of the day #78 https://t.co/w3a9demsYF
tweet

⁠Invest In Assets 📈
Buffett in August of 1979: https://t.co/QDFPSbdrD1
tweet

⁠Matt McGarry
My newsletter reached 25,000 subscribers.

Interesting finding about its growth:

The acquisition sources chart for the first 10,000 looks almost identical to the one for 25,000 subscribers.

Translation: Find winning levers, and pull them. https://t.co/wVPu0D5pXa
tweet

⁠Dimitry Nakhla | Babylon Capital®
A sober valuation analysis on $CRM 🧘🏽‍♂️

•NTM P/E Ratio: 24.18x
•1-Year Mean: 26.97x

•NTM FCF Yield: 5.12%
•1-Year Mean: 4.40%

As you can see, $CRM appears to be trading below fair value

Going forward, investors can expect to receive ~12% MORE in earnings per share & ~16% MORE in FCF per share🧠***

Before we get into valuation, let’s take a look at why $CRM is a good business

BALANCE SHEET✅
•Cash & Equivalents: $12.64B
•Long-Term Debt: $8.43B

$CRM has an excellent balance sheet, an A+ S&P Credit Rating & 352x FFO Interest Coverage Ratio

RETURN ON CAPITAL🆗
•2020: 1.2%
•2021: 0.9%
•2022: 0.8%
•2023: 2.5%
•2024: 8.2%
•LTM: 10.0%

RETURN ON EQUITY🆗
•2020: 0.5%
•2021: 10.8%
•2022: 2.9%
•2023: 0.4%
•2024: 7.0%
•LTM: 9.3%

$CRM return metrics are ok, although more recently trending in the right direction

REVENUES✅
•2014: $4.07B
•2024: $34.86B
•CAGR: 23.95%

FREE CASH FLOW✅
•2014: $576.36M
•2024: $9.49B
•CAGR: 32.34%

NORMALIZED EPS✅
•2014: $0.35
•2024: $8.22
•CAGR: 37.11%

SHARE BUYBACKS❌
•2014 Shares Outstanding: 597.61M
•LTM Shares Outstanding: 980.00M

By increasing its shares outstanding ~64%, $CRM diluted its EPS by ~40% (assuming 0 growth)

MARGINS✅
•LTM Gross Margins: 76.3%
•LTM Operating Margins: 19.1%
•LTM Net Income Margins: 15.4%

***NOW TO VALUATION 🧠

As stated above, investors can expect to receive ~12% MORE in EPS & ~16% MORE FCF per share

Using Benjamin Graham’s 2G rule of thumb, $CRM has to grow earnings at a 12.09% CAGR over the next several years to justify its valuation

Today, analysts anticipate 2025 - 2027 EPS growth over the next few years to be slightly more than the (12.09%) required growth rate:

2025E: $10.09 (22.8% YoY) *FY Jan
2026E: $11.13 (10.3% YoY)
2027E: $12.69 (14.0% YoY)

$CRM has an excellent track record of meeting analyst estimates ~2 years out, so let’s assume $CRM ends 2027 with $12.69 in EPS & see its CAGR potential assuming different multiples

26x P/E: $329.94💵 … ~12.4% CAGR

25x P/E: $317.25💵 … ~10.6% CAGR

24x P/E: $304.56💵 … ~8.8% CAGR

As you can see, we’d have to assume ~25x earnings for $CRM to have double digit CAGR potential (a multiple justified by its growth rate & moat)

Today at $252💵 $CRM appears to be worthwhile consideration for investment especially when you assess the trajectory of the company’s FCF & Net Income margins (steadily trending higher with further room to expand)

To ensure some margin of safety, if there’s further weakness, it could be wise to piece into the position, for example:

Initiating ~50% of the position at ~$252💵 & adding a second tranche at ~$210💵 or at ~20x NTM earnings

#stocks #investing
___

𝐃𝐈𝐒𝐂𝐋𝐎𝐒𝐔𝐑𝐄‼️: 𝐓𝐡𝐢𝐬 𝐢𝐬 𝐍𝐎𝐓 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐀𝐝𝐯𝐢𝐜𝐞. 𝐁𝐚𝐛𝐲𝐥𝐨𝐧 𝐂𝐚𝐩𝐢𝐭𝐚𝐥® 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐫𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐯𝐞𝐬 𝐦𝐚𝐲 𝐡𝐚𝐯𝐞 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭.

𝐓𝐡𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭 𝐢𝐬 𝐢𝐧𝐭𝐞𝐧𝐝𝐞𝐝 𝐟𝐨𝐫 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐩𝐮𝐫𝐩𝐨𝐬𝐞𝐬 𝐨𝐧𝐥𝐲 𝐚𝐧𝐝 𝐬𝐡𝐨𝐮𝐥𝐝 𝐧𝐨𝐭 𝐛𝐞 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐞𝐝 𝐚𝐬 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐚𝐝𝐯𝐢𝐜𝐞 𝐭𝐨 𝐦𝐞𝐞𝐭 𝐭𝐡𝐞 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐧𝐞𝐞𝐝𝐬 𝐨𝐟 𝐚𝐧𝐲 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥 𝐨𝐫 𝐬𝐢𝐭𝐮𝐚𝐭𝐢𝐨𝐧. 𝐏𝐚𝐬𝐭 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 𝐢𝐬 𝐧𝐨 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞 𝐨𝐟 𝐟𝐮𝐭𝐮𝐫𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬.

𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐨𝐛𝐭𝐚𝐢𝐧𝐞𝐝 𝐟𝐫𝐨𝐦 𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞, 𝐛𝐮𝐭 𝐢𝐬 𝐧𝐨𝐭 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞𝐝 𝐚𝐬 𝐭𝐨 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐧𝐞𝐬𝐬 𝐨𝐫 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲.
tweet

⁠Bourbon Capital
Good morning everyone, I hope you are having a good weekend

Welcome to September, the best month of the year for investors
tweet

⁠Bourbon Capital
Vaxcyte, Inc. $PCVX its up 31% premarket

Vaxcyte’s stock soars 31% after trial shows positive data for pneumococcal vaccine https://t.co/XZHcOC59jW
tweet